[Combination therapy in early rheumatoid arthritis: the COBRA study].
The scheme 'Combination therapy in rheumatoid arthritis' (COBRA) in early rheumatoid arthritis (RA) involves administration of not only sulfasalazine but also prednisolone and methotrexate during the first six months. The trial showed that the COBRA scheme over a period of 1.5 years was superior to sulfasalazine alone: less disease activity in the major part of the year of treatment, less articular damage on radiographs, fewer side effects and equal or reduced costs. An 'aggressive' treatment in patients with early RA is indicated, with (re)assessment of the use of corticosteroids.
Boers
M
M
Universiteit Maastricht, vakgroep Interne Geneeskunde/Reumatologie.
Verhoeven
A C
AC
van der Linden
S
S
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D018501:Antirheumatic Agents / Q000008:administration & dosage*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000191:economics / Q000473:pathology; D017281:Cost of Illness; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D006801:Humans; D007596:Joints / Q000473:pathology; D008727:Methotrexate / Q000008:administration & dosage; D011239:Prednisolone / Q000008:administration & dosage; D012460:Sulfasalazine / Q000008:administration & dosage
D000893:Anti-Inflammatory Agents; D018501:Antirheumatic Agents; D012460:Sulfasalazine; D011239:Prednisolone; D008727:Methotrexate